Iain Kilty
Director/Board Member at Octagon Therapeutics, Inc.
Iain Kilty active positions
| Companies | Position | Start | End |
|---|---|---|---|
Sitryx Therapeutics Ltd.
 Sitryx Therapeutics Ltd. Medical SpecialtiesHealth Technology Sitryx Therapeutics Ltd. Focuses on regulating cell metabolism to develop disease-modifying therapeutics in immuno-oncology and immuno-inflammation. It treats cancer and inflammatory conditions by targeting the metabolism of immune cells. The company was founded by Houman Ashrafian, Paul-Peter Tak, Luke O'Neill, Jonathan Powell, Jeff Rathmell and Michael Rosenblum and is headquartered in London, the United Kingdom. | Corporate Officer/Principal | 2021-03-31 | - |
SV Health Investors LLP
 SV Health Investors LLP Investment ManagersFinance SV Health Investors LLP (SV Health Investors) is a venture capital firm founded in 1994 by Peter McPartland. The firm is headquartered in London. | Private Equity Investor | 2022-02-28 | - |
Octagon Therapeutics, Inc.
 Octagon Therapeutics, Inc. BiotechnologyHealth Technology Octagon Therapeutics, Inc. engages in the research and development of medicines based on novel metabolic targets in disease-causing bacteria, lymphocytes, and cancer cells. It develops a discovery platform that identifies novel therapeutic targets and small molecule inhibitors that are invisible in standard culture conditions. The company was founded by Fred Ausubel, Isaac Stoner, and Shen Yu in 2016 and is headquartered in Allston, MA. | Director/Board Member | 2019-12-31 | - |
| Consultant / Advisor | 2019-12-31 | - |
Career history of Iain Kilty
Former positions of Iain Kilty
| Companies | Position | Start | End |
|---|---|---|---|
Quench Bio, Inc.
 Quench Bio, Inc. BiotechnologyHealth Technology Quench Bio, Inc. develops therapies targeting innate immune pathways to treat life-threatening auto-immune and inflammatory diseases. The company was founded by Mark J. Tebbe, Mike Nolan, and Arturo Zychlinsky and is headquartered in Cambridge, MA. | Corporate Officer/Principal | 2018-12-31 | 2021-03-31 |
| PFIZER, INC. | Private Equity Investor | 2013-02-28 | 2018-12-31 |
| Partners For Global Research&Development | Private Equity Investor | 2009-07-31 | 2011-07-31 |
Training of Iain Kilty
| University of Cambridge | Graduate Degree |
| University of Liverpool | Doctorate Degree |
Statistics
International
| United States | 6 |
| United Kingdom | 4 |
Operational
| Private Equity Investor | 3 |
| Corporate Officer/Principal | 2 |
| Director/Board Member | 1 |
Sectoral
| Health Technology | 5 |
| Consumer Services | 3 |
| Finance | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 1 |
|---|---|
| PFIZER, INC. | Health Technology |
| Private companies | 5 |
|---|---|
Sitryx Therapeutics Ltd.
Sitryx Therapeutics Ltd. Medical SpecialtiesHealth Technology Sitryx Therapeutics Ltd. Focuses on regulating cell metabolism to develop disease-modifying therapeutics in immuno-oncology and immuno-inflammation. It treats cancer and inflammatory conditions by targeting the metabolism of immune cells. The company was founded by Houman Ashrafian, Paul-Peter Tak, Luke O'Neill, Jonathan Powell, Jeff Rathmell and Michael Rosenblum and is headquartered in London, the United Kingdom. | Health Technology |
SV Health Investors LLP
SV Health Investors LLP Investment ManagersFinance SV Health Investors LLP (SV Health Investors) is a venture capital firm founded in 1994 by Peter McPartland. The firm is headquartered in London. | Finance |
Octagon Therapeutics, Inc.
Octagon Therapeutics, Inc. BiotechnologyHealth Technology Octagon Therapeutics, Inc. engages in the research and development of medicines based on novel metabolic targets in disease-causing bacteria, lymphocytes, and cancer cells. It develops a discovery platform that identifies novel therapeutic targets and small molecule inhibitors that are invisible in standard culture conditions. The company was founded by Fred Ausubel, Isaac Stoner, and Shen Yu in 2016 and is headquartered in Allston, MA. | Health Technology |
Quench Bio, Inc.
Quench Bio, Inc. BiotechnologyHealth Technology Quench Bio, Inc. develops therapies targeting innate immune pathways to treat life-threatening auto-immune and inflammatory diseases. The company was founded by Mark J. Tebbe, Mike Nolan, and Arturo Zychlinsky and is headquartered in Cambridge, MA. | Health Technology |
| Partners For Global Research&Development |
- Stock Market
- Insiders
- Iain Kilty
- Experience
